I have to give it a cautious endorsement just because its so damned interesting, even if I couldnt entirely find it in my heart to love it
The key is matching the right medication to the individual patients metabolic profilesomething our expert team addresses through functional assessments
Tang J, Kong B, Wu H, Xu M, Wang Y, Wang Y, et al
They took the time to answer all of my questions, explain the process in detail and took great care of me
In a Phase 2 NEJM-published trial (2023, n=338, 48 weeks), retatrutide at the highest dose produced mean body weight reduction of approximately 24% in adults with obesity
10.1007/s11926-008-0020-y 10